MX2019013110A - Anticuerpo anti-semaforina 4d humano. - Google Patents
Anticuerpo anti-semaforina 4d humano.Info
- Publication number
- MX2019013110A MX2019013110A MX2019013110A MX2019013110A MX2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A
- Authority
- MX
- Mexico
- Prior art keywords
- semaphorin
- antibody
- human anti
- diseases
- sema4d
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501981P | 2017-05-05 | 2017-05-05 | |
| PCT/US2018/031263 WO2018204895A1 (en) | 2017-05-05 | 2018-05-04 | Human anti-semaphorin 4d antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013110A true MX2019013110A (es) | 2019-12-16 |
Family
ID=64016767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013110A MX2019013110A (es) | 2017-05-05 | 2018-05-04 | Anticuerpo anti-semaforina 4d humano. |
| MX2023003519A MX2023003519A (es) | 2017-05-05 | 2019-11-04 | Anticuerpo anti-semaforina 4d humano. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003519A MX2023003519A (es) | 2017-05-05 | 2019-11-04 | Anticuerpo anti-semaforina 4d humano. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11427634B2 (https=) |
| EP (1) | EP3618865A4 (https=) |
| JP (3) | JP7246320B2 (https=) |
| KR (1) | KR102680924B1 (https=) |
| CN (1) | CN110636858B (https=) |
| AU (2) | AU2018261947B2 (https=) |
| BR (1) | BR112019023138A2 (https=) |
| CA (1) | CA3061963A1 (https=) |
| IL (1) | IL270244B2 (https=) |
| MX (2) | MX2019013110A (https=) |
| NZ (1) | NZ758300A (https=) |
| SG (1) | SG11201909466RA (https=) |
| WO (1) | WO2018204895A1 (https=) |
| ZA (1) | ZA201907148B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| WO2018204895A1 (en) * | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| CA3152371A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| IL311639A (en) | 2021-09-27 | 2024-05-01 | Vaccinex Inc | Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| KR102875105B1 (ko) * | 2023-04-03 | 2025-10-21 | 주식회사 사이알바이오 | 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물 |
| CN117924494B (zh) * | 2024-01-23 | 2025-02-25 | 首都医科大学附属北京积水潭医院 | 特异性结合sema4d的抗原结合蛋白及其应用 |
| WO2026030311A1 (en) | 2024-07-29 | 2026-02-05 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules to treat cognitive impairment |
| WO2026080818A1 (en) | 2024-10-10 | 2026-04-16 | Vaccinex, Inc. | Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| EP1340088B1 (en) | 2000-11-17 | 2007-01-17 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| ES2567402T3 (es) | 2006-05-30 | 2016-04-22 | Genentech, Inc. | Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos |
| TW200817437A (en) | 2006-08-11 | 2008-04-16 | Medarex Inc | Monoclonal antibodies against stromal cell derived factor-1 (SDF-1) |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| FI20075278A0 (fi) | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| EP2157937B1 (en) | 2007-06-04 | 2017-03-22 | Sequent Medical, Inc. | Devices for treatment of vascular defects |
| RU2581962C2 (ru) | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Нацеленные средства связывания, направленные на dll4, и их применение |
| ES2647823T3 (es) * | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| KR102003571B1 (ko) * | 2011-05-13 | 2019-07-24 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 골형성 촉진제 |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US9090709B2 (en) * | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CN104127862A (zh) * | 2014-08-14 | 2014-11-05 | 武汉大学 | Semaphorin 4D在预防及治疗骨代谢性疾病中的应用 |
| CN107108728A (zh) * | 2014-12-15 | 2017-08-29 | 莫佛塞斯公司 | Il‑17c的抗体 |
| WO2018204895A1 (en) * | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| US11597765B2 (en) * | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
-
2018
- 2018-05-04 WO PCT/US2018/031263 patent/WO2018204895A1/en not_active Ceased
- 2018-05-04 IL IL270244A patent/IL270244B2/en unknown
- 2018-05-04 KR KR1020197034009A patent/KR102680924B1/ko active Active
- 2018-05-04 JP JP2019560083A patent/JP7246320B2/ja active Active
- 2018-05-04 CA CA3061963A patent/CA3061963A1/en active Pending
- 2018-05-04 AU AU2018261947A patent/AU2018261947B2/en active Active
- 2018-05-04 MX MX2019013110A patent/MX2019013110A/es unknown
- 2018-05-04 SG SG11201909466R patent/SG11201909466RA/en unknown
- 2018-05-04 US US16/611,209 patent/US11427634B2/en active Active
- 2018-05-04 EP EP18793831.1A patent/EP3618865A4/en active Pending
- 2018-05-04 BR BR112019023138-2A patent/BR112019023138A2/pt unknown
- 2018-05-04 CN CN201880029632.7A patent/CN110636858B/zh active Active
- 2018-05-04 NZ NZ758300A patent/NZ758300A/en unknown
-
2019
- 2019-10-29 ZA ZA2019/07148A patent/ZA201907148B/en unknown
- 2019-11-04 MX MX2023003519A patent/MX2023003519A/es unknown
-
2022
- 2022-07-19 US US17/813,375 patent/US12006365B2/en active Active
-
2023
- 2023-03-14 JP JP2023039438A patent/JP7460819B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044422A patent/JP2024081694A/ja active Pending
- 2024-05-03 US US18/654,538 patent/US20240309091A1/en active Pending
- 2024-07-10 AU AU2024204752A patent/AU2024204752A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7246320B2 (ja) | 2023-03-27 |
| KR102680924B1 (ko) | 2024-07-02 |
| BR112019023138A2 (pt) | 2020-07-28 |
| JP7460819B2 (ja) | 2024-04-02 |
| WO2018204895A1 (en) | 2018-11-08 |
| IL270244B1 (en) | 2024-09-01 |
| US20220356249A1 (en) | 2022-11-10 |
| JP2020518248A (ja) | 2020-06-25 |
| IL270244A (en) | 2019-12-31 |
| RU2019131732A3 (https=) | 2021-09-28 |
| KR20200004324A (ko) | 2020-01-13 |
| US11427634B2 (en) | 2022-08-30 |
| CN110636858B (zh) | 2024-03-19 |
| EP3618865A4 (en) | 2021-05-05 |
| US12006365B2 (en) | 2024-06-11 |
| US20240309091A1 (en) | 2024-09-19 |
| EP3618865A1 (en) | 2020-03-11 |
| ZA201907148B (en) | 2025-06-25 |
| MX2023003519A (es) | 2023-04-19 |
| IL270244B2 (en) | 2025-01-01 |
| AU2018261947A1 (en) | 2019-11-07 |
| JP2023075271A (ja) | 2023-05-30 |
| AU2024204752A1 (en) | 2024-08-01 |
| JP2024081694A (ja) | 2024-06-18 |
| US20210032329A1 (en) | 2021-02-04 |
| NZ758300A (en) | 2025-11-28 |
| SG11201909466RA (en) | 2019-11-28 |
| CN110636858A (zh) | 2019-12-31 |
| CA3061963A1 (en) | 2018-11-08 |
| AU2018261947B2 (en) | 2024-06-13 |
| RU2019131732A (ru) | 2021-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003519A (es) | Anticuerpo anti-semaforina 4d humano. | |
| MX2023002588A (es) | Anticuerpos anti-tgf-beta y su uso. | |
| MX2022010224A (es) | Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| PH12017501402A1 (en) | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| ZA201801852B (en) | Anti¿pd¿1 antibodies and compositions | |
| SA518391831B1 (ar) | تركيبات وطرق لخفض تعبير البروتين تاو | |
| MX2022014762A (es) | Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso. | |
| WO2016086175A8 (en) | Effector-deficient anti-cd32a antibodies | |
| IL281449A (en) | Anti-ifnar1 antibodies for the treatment of autoimmune diseases | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| MX385868B (es) | Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias. | |
| MX2019011423A (es) | Metodos de tratamiento de enfermedades neurodegenerativas. | |
| GEP20217253B (en) | ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF | |
| WO2018134681A8 (en) | Anti-tgf-beta antibodies and their use | |
| IL281441A (en) | Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| HK1255056A1 (zh) | 抗cd115抗体 | |
| PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
| MA40536A (fr) | Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations | |
| HK40038634A (en) | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer | |
| HK40039204A (en) | Anti-ifnar1 antibodies for treating autoimmune diseases |